JP2005505586A - ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 - Google Patents
５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 Download PDFInfo
- Publication number
- JP2005505586A JP2005505586A JP2003532487A JP2003532487A JP2005505586A JP 2005505586 A JP2005505586 A JP 2005505586A JP 2003532487 A JP2003532487 A JP 2003532487A JP 2003532487 A JP2003532487 A JP 2003532487A JP 2005505586 A JP2005505586 A JP 2005505586A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- amino
- chromen
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title description 6
- 239000003446 ligand Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 108091005435 5-HT6 receptors Proteins 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- -1 cycloheteroalkyl Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- KTOFKMSCCFJWBS-VGOFRKELSA-N 4-amino-n-[(2r)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-VGOFRKELSA-N 0.000 claims description 3
- YBSRWLPYDCLVSK-QRIPLOBPSA-N 5-chloro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(Cl)S1 YBSRWLPYDCLVSK-QRIPLOBPSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- MPUPRKCXYAKXGG-NLFFAJNJSA-N n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NC[C@H]2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-NLFFAJNJSA-N 0.000 claims description 3
- JBOQIPSUVREQCA-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNCCCO)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 JBOQIPSUVREQCA-UHFFFAOYSA-N 0.000 claims description 3
- LYKLVYXZKFKQCL-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4CCC(OC4=C3)CNCCCO)=CC=C21 LYKLVYXZKFKQCL-UHFFFAOYSA-N 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- ILLXJTSTTAHMPW-ZZWBGTBQSA-N 2-bromo-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=CC=C1Br ILLXJTSTTAHMPW-ZZWBGTBQSA-N 0.000 claims description 2
- BIGOYIJVKGTZJZ-HWYAHNCWSA-N 3,4-dimethoxy-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N(C)C1=CC=C(CCC(CN[C@H](C)C=2C=CC=CC=2)O2)C2=C1 BIGOYIJVKGTZJZ-HWYAHNCWSA-N 0.000 claims description 2
- KTOFKMSCCFJWBS-VGSWGCGISA-N 4-amino-n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-VGSWGCGISA-N 0.000 claims description 2
- KTOFKMSCCFJWBS-PLEWWHCXSA-N 4-amino-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-PLEWWHCXSA-N 0.000 claims description 2
- DQNREVMJMGBQKN-FKSKYRLFSA-N 4-amino-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(N)C=C1 DQNREVMJMGBQKN-FKSKYRLFSA-N 0.000 claims description 2
- AWIXQIBWRFBSEK-PLEWWHCXSA-N 4-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Cl)C=C1 AWIXQIBWRFBSEK-PLEWWHCXSA-N 0.000 claims description 2
- FJNWVEWEYQRAJK-FKSKYRLFSA-N 4-chloro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(Cl)C=C1 FJNWVEWEYQRAJK-FKSKYRLFSA-N 0.000 claims description 2
- RRFQIUAANMAPNG-FKSKYRLFSA-N 4-fluoro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(F)C=C1 RRFQIUAANMAPNG-FKSKYRLFSA-N 0.000 claims description 2
- ZIOGBNJAFVMADK-FKSKYRLFSA-N 4-methoxy-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(CCC(CN[C@H](C)C=2C=CC=CC=2)O2)C2=C1 ZIOGBNJAFVMADK-FKSKYRLFSA-N 0.000 claims description 2
- WZGAORUXLKNXSB-HWYAHNCWSA-N 4-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C)C=C1 WZGAORUXLKNXSB-HWYAHNCWSA-N 0.000 claims description 2
- NCELXXSBJZTWHQ-NYRJJRHWSA-N 5-bromo-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Br)S1 NCELXXSBJZTWHQ-NYRJJRHWSA-N 0.000 claims description 2
- FWOQQSYVHAAAIO-FKSKYRLFSA-N 5-chloro-3-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-1-benzothiophene-2-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C4=C(C5=CC(Cl)=CC=C5S4)C)=CC=C3CC2)C)=CC=CC=C1 FWOQQSYVHAAAIO-FKSKYRLFSA-N 0.000 claims description 2
- ITCPCWOZLJVHMY-NYRJJRHWSA-N 5-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Cl)S1 ITCPCWOZLJVHMY-NYRJJRHWSA-N 0.000 claims description 2
- YQSSZSAYMFYLAK-NYRJJRHWSA-N 6-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4N5C=CSC5=NC=4Cl)=CC=C3CC2)C)=CC=CC=C1 YQSSZSAYMFYLAK-NYRJJRHWSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- MPUPRKCXYAKXGG-CJFMBICVSA-N n-[(2r)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NC[C@@H]2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-CJFMBICVSA-N 0.000 claims description 2
- JUSHGQIHSMKQER-UHFFFAOYSA-N n-[2-(morpholin-4-ylmethyl)-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CN1CCOCC1 JUSHGQIHSMKQER-UHFFFAOYSA-N 0.000 claims description 2
- KNXWOCYAYPNERT-UHFFFAOYSA-N n-[2-(thiomorpholin-4-ylmethyl)-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CN1CCSCC1 KNXWOCYAYPNERT-UHFFFAOYSA-N 0.000 claims description 2
- KQVPFHLRRUPWLC-UHFFFAOYSA-N n-[2-[(1,2-diphenylethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNC(C=1C=CC=CC=1)CC1=CC=CC=C1 KQVPFHLRRUPWLC-UHFFFAOYSA-N 0.000 claims description 2
- QDRJYKADDYSPBW-UHFFFAOYSA-N n-[2-[(1,3-benzodioxol-5-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=C2CCC(CNCC=3C=C4OCOC4=CC=3)OC2=CC=1NS(=O)(=O)C1=CC=CC=C1 QDRJYKADDYSPBW-UHFFFAOYSA-N 0.000 claims description 2
- ORLIARKOZBWBEA-UHFFFAOYSA-N n-[2-[(2,3-dihydro-1h-inden-1-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=C2CCC(CNC3C4=CC=CC=C4CC3)OC2=CC=1NS(=O)(=O)C1=CC=CC=C1 ORLIARKOZBWBEA-UHFFFAOYSA-N 0.000 claims description 2
- XREPGWKDFACLAF-UHFFFAOYSA-N n-[2-[(2,6-dimethylpiperidin-1-yl)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound CC1CCCC(C)N1CC1OC2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2CC1 XREPGWKDFACLAF-UHFFFAOYSA-N 0.000 claims description 2
- VFBAHPKGBZTJNB-UHFFFAOYSA-N n-[2-[(3-butoxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNCCCOCCCC)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 VFBAHPKGBZTJNB-UHFFFAOYSA-N 0.000 claims description 2
- GVHRPFFOWXVQLX-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(CCC(CNCCCO)O2)C2=C1 GVHRPFFOWXVQLX-UHFFFAOYSA-N 0.000 claims description 2
- NMNLZKVFAIEKKD-UHFFFAOYSA-N n-[2-[(3-phenoxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCCCOC1=CC=CC=C1 NMNLZKVFAIEKKD-UHFFFAOYSA-N 0.000 claims description 2
- FQUZKJPVIJUETI-UHFFFAOYSA-N n-[2-[(4-phenylbutan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1CC2=CC=C(NS(=O)(=O)C=3C=CC=CC=3)C=C2OC1CNC(C)CCC1=CC=CC=C1 FQUZKJPVIJUETI-UHFFFAOYSA-N 0.000 claims description 2
- HXOIGDPVNAKTPZ-UHFFFAOYSA-N n-[2-[(6-methylheptan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)CCCC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 HXOIGDPVNAKTPZ-UHFFFAOYSA-N 0.000 claims description 2
- CRIAMUZXQQEDGS-UHFFFAOYSA-N n-[2-[(benzylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=CC=C1 CRIAMUZXQQEDGS-UHFFFAOYSA-N 0.000 claims description 2
- GUOCWZSITCMHCG-UHFFFAOYSA-N n-[2-[(propan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 GUOCWZSITCMHCG-UHFFFAOYSA-N 0.000 claims description 2
- IJURTMPWEYPMSZ-UHFFFAOYSA-N n-[2-[(pyridin-3-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=CN=C1 IJURTMPWEYPMSZ-UHFFFAOYSA-N 0.000 claims description 2
- GJXCJBIDAZVKSP-UHFFFAOYSA-N n-[2-[(pyridin-4-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=NC=C1 GJXCJBIDAZVKSP-UHFFFAOYSA-N 0.000 claims description 2
- GBKCFXXCHCAHQA-UHFFFAOYSA-N n-[2-[[(1-hydroxy-2-methylpropan-2-yl)amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)(CO)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 GBKCFXXCHCAHQA-UHFFFAOYSA-N 0.000 claims description 2
- SZTSARCCKVNOPN-UHFFFAOYSA-N n-[2-[[(3-methoxyphenyl)methylamino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound COC1=CC=CC(CNCC2OC3=CC(NS(=O)(=O)C=4C=CC=CC=4)=CC=C3CC2)=C1 SZTSARCCKVNOPN-UHFFFAOYSA-N 0.000 claims description 2
- KSFITRJYLAFIHR-UHFFFAOYSA-N n-[2-[[2-(2-hydroxyethyl)piperidin-1-yl]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound OCCC1CCCCN1CC1OC2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2CC1 KSFITRJYLAFIHR-UHFFFAOYSA-N 0.000 claims description 2
- IZDZOJUPEPKONT-ZZWBGTBQSA-N n-[2-[[[(1r)-1-cyclohexylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C1CCCCC1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 IZDZOJUPEPKONT-ZZWBGTBQSA-N 0.000 claims description 2
- QLSUJDYZWSBRGE-QRIPLOBPSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-2,1,3-benzoxadiazole-4-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4C5=NON=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 QLSUJDYZWSBRGE-QRIPLOBPSA-N 0.000 claims description 2
- SMXLSSFADRHULS-PLEWWHCXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 SMXLSSFADRHULS-PLEWWHCXSA-N 0.000 claims description 2
- NDCPPWBMKVPNDX-PLEWWHCXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 NDCPPWBMKVPNDX-PLEWWHCXSA-N 0.000 claims description 2
- ROQBLRJFXQWFLB-ZZWBGTBQSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-ZZWBGTBQSA-N 0.000 claims description 2
- MPUPRKCXYAKXGG-VGOKPJQXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-VGOKPJQXSA-N 0.000 claims description 2
- OCRAGFDGDHKJRX-YANBTOMASA-N n-[2-[[[(1r)-2-hydroxy-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@@H](CO)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 OCRAGFDGDHKJRX-YANBTOMASA-N 0.000 claims description 2
- ROQBLRJFXQWFLB-HXBUSHRASA-N n-[2-[[[(1s)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-HXBUSHRASA-N 0.000 claims description 2
- IQANGFUDFZONKO-FIWHBWSRSA-N n-[2-[[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CN[C@@H](CO)CC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 IQANGFUDFZONKO-FIWHBWSRSA-N 0.000 claims description 2
- DIBJLKROTYKRAC-RBFZIWAESA-N n-[4-methyl-5-[[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]sulfamoyl]-1,3-thiazol-2-yl]acetamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C=1SC(NC(C)=O)=NC=1C DIBJLKROTYKRAC-RBFZIWAESA-N 0.000 claims description 2
- RGDYZZALLDWINK-OSMGYRLQSA-N n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(=CC=C3CC2)N(C)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C)=CC=CC=C1 RGDYZZALLDWINK-OSMGYRLQSA-N 0.000 claims description 2
- 125000000962 organic group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- ROQBLRJFXQWFLB-GCJKJVERSA-N n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-GCJKJVERSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 208000015114 central nervous system disease Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IXWDJADQKFBZEA-UHFFFAOYSA-N (7-amino-3,4-dihydro-2h-chromen-2-yl)methanol Chemical compound C1CC(CO)OC2=CC(N)=CC=C21 IXWDJADQKFBZEA-UHFFFAOYSA-N 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000010183 spectrum analysis Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 0 CC1(*)c2ccc(*)cc2OC(*)C1(*)* Chemical compound CC1(*)c2ccc(*)cc2OC(*)C1(*)* 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- QDYAIISJDSNGFN-UHFFFAOYSA-N [7-(benzenesulfonamido)-3,4-dihydro-2h-chromen-2-yl]methyl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2COS(=O)(=O)C1=CC=CC=C1 QDYAIISJDSNGFN-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XAJQENIVBSZOMM-UHFFFAOYSA-N ethyl 7-amino-3,4-dihydro-2h-chromene-2-carboxylate Chemical compound C1=C(N)C=C2OC(C(=O)OCC)CCC2=C1 XAJQENIVBSZOMM-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UKTKWGFGIAAFRG-UHFFFAOYSA-N [7-(methylamino)-3,4-dihydro-2h-chromen-2-yl]methanol Chemical compound C1CC(CO)OC2=CC(NC)=CC=C21 UKTKWGFGIAAFRG-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- CNWVQPJMIBPYKK-UHFFFAOYSA-N ethyl 7-amino-4-oxochromene-2-carboxylate Chemical compound C1=C(N)C=C2OC(C(=O)OCC)=CC(=O)C2=C1 CNWVQPJMIBPYKK-UHFFFAOYSA-N 0.000 description 2
- ZWUGUBVUYGAMIN-UHFFFAOYSA-N ethyl 7-formamido-3,4-dihydro-2h-chromene-2-carboxylate Chemical compound C1=C(NC=O)C=C2OC(C(=O)OCC)CCC2=C1 ZWUGUBVUYGAMIN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- ZSSHNMZQDWSUJJ-UHFFFAOYSA-N n-(4-acetyl-3-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C(C)=O)C(O)=C1 ZSSHNMZQDWSUJJ-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HMXJOWDZAJWLTF-UHFFFAOYSA-N 2h-chromene-2-carboxylic acid Chemical compound C1=CC=C2C=CC(C(=O)O)OC2=C1 HMXJOWDZAJWLTF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003591 cerebellar nuclei Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- ROQBLRJFXQWFLB-XMSQKQJNSA-N n-[(2r)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-XMSQKQJNSA-N 0.000 description 1
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 1
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32695701P | 2001-10-04 | 2001-10-04 | |
| PCT/US2002/030955 WO2003029238A1 (en) | 2001-10-04 | 2002-09-30 | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505586A true JP2005505586A (ja) | 2005-02-24 |
| JP2005505586A5 JP2005505586A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
Family
ID=23274503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532487A Pending JP2005505586A (ja) | 2001-10-04 | 2002-09-30 | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6706757B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1432696A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005505586A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1561338A (cg-RX-API-DMAC7.html) |
| BR (1) | BR0213094A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2461381A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04003087A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003029238A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514828A (ja) * | 2005-11-03 | 2009-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体 |
| JP2011518858A (ja) * | 2008-04-29 | 2011-06-30 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| JP2007536302A (ja) * | 2004-05-05 | 2007-12-13 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体、５−ｈｔ２ａ受容体、又はその両方の調節に有用なアリールスルホニルベンゾジオキサン類 |
| ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
| RU2382036C2 (ru) * | 2004-09-30 | 2010-02-20 | Ф.Хоффманн-Ля Рош Аг | Производные бензоксазина и хиноксалина и их применение |
| WO2006040178A1 (en) * | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co.Kg | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor |
| WO2006066745A1 (en) * | 2004-12-21 | 2006-06-29 | F.Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
| RU2396266C2 (ru) * | 2004-12-21 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные хромана и их применения при лечении заболеваний цнс |
| EP1831152B1 (en) * | 2004-12-21 | 2008-09-24 | F. Hoffmann-La Roche AG | Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
| JP2008524275A (ja) * | 2004-12-21 | 2008-07-10 | エフ．ホフマン−ラ ロシュ アーゲー | クロマン誘導体及び５−ｈｔレセプターリガンドとしてのそれらの使用 |
| MX2007007558A (es) * | 2004-12-21 | 2007-07-24 | Hoffmann La Roche | Derivados de tetralina y de indano y usos de los mismos. |
| TW200640931A (en) | 2005-02-17 | 2006-12-01 | Wyeth Corp | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
| TW200716595A (en) * | 2005-04-22 | 2007-05-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| WO2006116218A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| BRPI0610044A2 (pt) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | combinações terapêuticas para o tratamento ou prevenção de depressão |
| AR054363A1 (es) * | 2005-05-23 | 2007-06-20 | Astrazeneca Ab | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
| AR054044A1 (es) * | 2005-05-23 | 2007-05-30 | Astrazeneca Ab | Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad. |
| JP2009541249A (ja) * | 2006-06-20 | 2009-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | アリールスルホニルナフタレン誘導体およびその使用 |
| CN101472883A (zh) * | 2006-06-20 | 2009-07-01 | 弗·哈夫曼-拉罗切有限公司 | 芳基磺酰氨基四氢萘衍生物以及其应用 |
| AU2007263084A1 (en) * | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
| CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
| TW200831478A (en) * | 2006-10-25 | 2008-08-01 | Wyeth Corp | Chromane derivatives, synthesis thereof, and intermediates thereto |
| AU2009242095A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4135474A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| ATE191716T1 (de) * | 1992-08-17 | 2000-04-15 | Chugai Pharmaceutical Co Ltd | Benzopyran und benzoxazin-derivate |
| US6448269B1 (en) * | 1993-07-22 | 2002-09-10 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
| SK282402B6 (sk) | 1993-08-19 | 2002-01-07 | Janssen Pharmaceutica N. V. | Deriváty dihydrobenzopyránu, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutický prostriedok na ich báze |
| US5663194A (en) * | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| US6191164B1 (en) * | 1996-05-15 | 2001-02-20 | Hoechst Aktiengesellschaft | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them |
| PT1027043E (pt) * | 1996-12-10 | 2005-02-28 | Bristol Myers Squibb Co | Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6051586A (en) * | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| IL136688A0 (en) * | 1997-12-19 | 2001-06-14 | Bayer Ag | Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| GB9813949D0 (en) * | 1998-06-29 | 1998-08-26 | Smithkline Beecham Plc | Novel compounds |
| CN1318413C (zh) * | 1998-09-23 | 2007-05-30 | 研究发展基金会 | 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
| FR2787789B1 (fr) * | 1998-12-29 | 2002-06-14 | Lipha | Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| ATE309995T1 (de) * | 1999-08-26 | 2005-12-15 | Aventis Pharma Inc | Substituierte (aminoiminomethyl oder aminomethyl) dihydrobenzofurane und benozopyrane |
| EP1212314B1 (en) * | 1999-09-17 | 2005-11-30 | Nissan Chemical Industries, Ltd. | Benzopyran derivative |
| US6323238B1 (en) * | 1999-10-21 | 2001-11-27 | Dongbu Hannong Chemical Co., Ltd. | Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
-
2002
- 2002-09-30 CA CA002461381A patent/CA2461381A1/en not_active Abandoned
- 2002-09-30 BR BR0213094-7A patent/BR0213094A/pt not_active IP Right Cessation
- 2002-09-30 EP EP02800383A patent/EP1432696A1/en not_active Withdrawn
- 2002-09-30 WO PCT/US2002/030955 patent/WO2003029238A1/en not_active Ceased
- 2002-09-30 MX MXPA04003087A patent/MXPA04003087A/es unknown
- 2002-09-30 JP JP2003532487A patent/JP2005505586A/ja active Pending
- 2002-09-30 CN CNA028193342A patent/CN1561338A/zh active Pending
- 2002-10-02 US US10/263,890 patent/US6706757B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514828A (ja) * | 2005-11-03 | 2009-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体 |
| JP2011518858A (ja) * | 2008-04-29 | 2011-06-30 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030158175A1 (en) | 2003-08-21 |
| CA2461381A1 (en) | 2003-04-10 |
| US6706757B2 (en) | 2004-03-16 |
| EP1432696A1 (en) | 2004-06-30 |
| CN1561338A (zh) | 2005-01-05 |
| WO2003029238A1 (en) | 2003-04-10 |
| MXPA04003087A (es) | 2004-09-06 |
| BR0213094A (pt) | 2004-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505586A (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 | |
| US6638972B2 (en) | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands | |
| TW593278B (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| TWI282787B (en) | 1-aryl-or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
| JP4335684B2 (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのインドリルアルキルアミン誘導体 | |
| JP5031846B2 (ja) | ５−ｈｔ（５ａ）受容体アンタゴニストとしての２−アミノキノリン | |
| AU2002251811A1 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| JP2006518385A (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルインダゾール | |
| EP0399982B1 (en) | Novel 8-substituted-2-amino-tetralines | |
| JP2001512727A (ja) | ５ｈｔ−１受容体のリガンドとしてのニ環式化合物 | |
| JP2003503492A (ja) | メラトニン作用剤としての複素環式アミノピロリジン誘導体 | |
| JPH0692852A (ja) | ベンゾビサイクリックカルボキサミドを用いた不安症の緩和方法 | |
| AU2002344949A1 (en) | Novel heteroaryl derivatives, their preparation and use | |
| WO2003002556A1 (en) | Novel heteroaryl derivatives, their preparation and use | |
| JP6943239B2 (ja) | Ｋｃｎｑ２〜５チャネル活性化剤 | |
| US20030203895A1 (en) | Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | |
| JP2001508419A (ja) | ５−ｈｔ受容体活性を有するスルホンアミド化合物 | |
| JP2008500383A (ja) | ５−ｈｔ１ｂアンタゴニスト、インバースアゴニストおよび部分アゴニストとしてのテトラヒドロナフチルピペラジン類 | |
| WO2005037830A1 (en) | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | |
| JP2001512491A (ja) | １−（イソキノリン−１−イル）−４−（１−フェニメチル）ピペラジン；ドーパミン受容体サブタイプ特異的リガンド | |
| JP2008504267A (ja) | ５−ヒドロキシトリプタミン−６配位子としてのインドリルアルキルアミン代謝物 | |
| JPH08507512A (ja) | ５‐ｈｔ１ａ拮抗物質として有用な４‐アミノ‐２‐（ヘテロ）アリール‐ブタンアミド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050401 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050401 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407 |